Syntrix Biosystems, Inc.

Auburn, WA 98001

SBIR Award Summary

Total Number of Awards 56
Total Value of Awards $25.7MM
Active Awards 3 valued at $1.95MM
First Award Date 08/01/01
Most Recent Award Date 09/01/17

3 Active Awards Valued at $1.95MM

Award Title Awarding Agency Phase Award amount Start Date End Date
Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers: A Phase 1 Trial Demonstrating Analgesic ... HHS 2 $998K 09/01/17 08/31/18
Phase II clinical evaluation of Omnitram in neuropathic pain HHS 2 $657K 08/01/17 07/31/18
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 ... HHS 2 $300K 05/04/17 04/30/18

Key Personnel

Last Name Name Awards Contact
Zebala John A Zebala 48
Goldstein Alex Goldstein 2
Maeda Dean Yoshimasa Maeda 8
Morgan Joel R Morgan 11
Kahn Stuart J Kahn 16

56 Awards Won

Phase 2 SBIR Active

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 09/01/17 - 08/31/18

? DESCRIPTION (provided by applicant): From 2009-2013 the utilization of the Schedule II opioids codeine, OxyContin and fentanyl declined significantly, down about 14.0% for all three drugs. In sharp contrast, the use of tramadol, a Schedule IV controlled substance, increased 32.5%. Schedule IV substances have low potential for abuse and harm...

Phase 2 SBIR Active

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 08/01/17 - 07/31/18

? DESCRIPTION (provided by applicant): Neuropathic pain is caused by damage to the peripheral nerves, as occurs in diabetic neuropathy. Neuropathic pain is difficult to treat, and many patients have pain that is refractory to existing treatments. Omnitram is a novel mixed-mechanism analgesic developed by Syntrix that consists of the (-) and (...

Phase 2 SBIR Active

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 05/04/17 - 04/30/18

The chemokine receptors CXCR1 and CXCR2 (CXCR1/2) are validated as having essential roles in the growth, survival, motility, invasion and angiogenesis of human melanoma, which secretes abundant amounts of the corresponding chemokine ligands, including CXCL8. Additionally, abnormal cancer-induced immunosuppressive myeloid-derived suppressor cells...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-13-250
Budget: 02/01/17 - 01/31/18

DESCRIPTION (provided by applicant): Psoriasis is a chronic, genetically influenced, remitting and relapsing scaly and inflammatory skin disorder that affects 1-3% of the world's population, resulting in total annual costs of $5.2 billion in the United States in 2012. Approximately 20% of patients with moderate-to-severe chronic plaque psoriasis...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 09/01/16 - 08/31/17

? DESCRIPTION (provided by applicant): From 2009-2013 the utilization of the Schedule II opioids codeine, OxyContin and fentanyl declined significantly, down about 14.0% for all three drugs. In sharp contrast, the use of tramadol, a Schedule IV controlled substance, increased 32.5%. Schedule IV substances have low potential for abuse and har...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 08/01/16 - 07/31/17

? DESCRIPTION (provided by applicant): Neuropathic pain is caused by damage to the peripheral nerves, as occurs in diabetic neuropathy. Neuropathic pain is difficult to treat, and many patients have pain that is refractory to existing treatments. Omnitram is a novel mixed-mechanism analgesic developed by Syntrix that consists of the (-) and (+...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-13-250
Budget: 02/19/16 - 01/31/17

DESCRIPTION (provided by applicant): Psoriasis is a chronic, genetically influenced, remitting and relapsing scaly and inflammatory skin disorder that affects 1-3% of the world's population, resulting in total annual costs of $5.2 billion in the United States in 2012. Approximately 20% of patients with moderate-to-severe chronic plaque psoriasis...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 08/01/15 - 07/31/16

DESCRIPTION (provided by applicant): Neuropathic pain is caused by damage to the peripheral nerves, as occurs in diabetic neuropathy. Neuropathic pain is difficult to treat, and many patients have pain that is refractory to existing treatments. Omnitram is a novel mixed-mechanism analgesic developed by Syntrix that consists of the (-) and (+) en...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 08/01/14 - 07/31/15

DESCRIPTION (provided by applicant): Tramadol is a widely prescribed analgesic, with over 25 million prescriptions and $565 million in retail sales in 2009, making it among the best selling generic drugs. One of the advantages of tramadol over traditional opioids is its lower risk of opioid dependence, resulting in it having an unscheduled statu...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-13-250
Budget: 08/01/14 - 07/31/15

DESCRIPTION (provided by applicant): Psoriasis is a chronic, genetically influenced, remitting and relapsing scaly and inflammatory skin disorder that affects 1-3% of the world's population, resulting in total annual costs of $5.2 billion in the United States in 2012. Approximately 20% of patients with moderate-to-severe chronic plaque psoriasis...

Load More